HRT Financial’s TG Therapeutics TGTX Stock Holding History

HRT Financial’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.2M	Buy	622,603 +478,132	+331%	+$19.6M	0.06%	284
2026 Q1	$4.8M	Sell	144,471 -50,888	-26%	-$1.52M	0.01%	1023
2025 Q4	$5.82M	Buy	195,359 +87,078	+80%	+$2.84M	0.02%	706
2025 Q3	$3.91M	Buy	+108,281	New	+$3.57M	0.01%	794
2024 Q1	–	Sell	-76,543	Closed	-$1.31M	–	3080
2023 Q4	$1.31M	Buy	+76,543	New	+$890K	0.01%	862
2023 Q3	–	Sell	-20,868	Closed	-$518K	–	3087
2023 Q2	$518K	Sell	20,868 -188,044	-90%	-$4.86M	﹤0.01%	1343
2023 Q1	$3.14M	Buy	208,912 +47,452	+29%	+$721K	0.04%	416
2022 Q4	$1.91M	Buy	161,460 +75,483	+88%	+$548K	0.03%	616
2022 Q3	$508K	Buy	+85,977	New	+$564K	0.01%	1448
2019 Q4	–	Sell	-12,894	Closed	-$72K	–	1632
2019 Q3	$72K	Buy	+12,894	New	+$89.9K	﹤0.01%	1275

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

HRT Financial's TGTX Position: Q2 2026 in Review

HRT Financial increased its TG Therapeutics (TGTX) stake by 331% in Q2 2026, buying an estimated $19.6M and bringing the position to 622,603 shares worth $34.2M. The position accounts for 0.06% of the portfolio, ranked #284.

HRT Financial first reported a position in TGTX in Q3 2019 and has held it in 10 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

HRT Financial held 622,603 shares of TG Therapeutics worth $34.2M as of Q2 2026.
HRT Financial bought 478,132 TG Therapeutics shares in Q2 2026, an estimated $19.6M.
TG Therapeutics made up 0.06% of HRT Financial's portfolio in Q2 2026, its #284 holding.
HRT Financial first reported a position in TG Therapeutics in Q3 2019 and has held it in 10 quarters since.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.